The industry is also bracing itself for the impact of U.S. President Donald Trump's sweeping tariffs on most imports, which have forced companies to contend with higher raw material costs and ...

Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose ...